Therapeutics: CXC chemokine receptor 4 (CXCR4; NPY3R); lymphocyte-specific protein kinase (LCK) Provisional patent application filed; available for licensing

Autoimmune disease

INDICATION: Autoimmune disease

In vitro studies suggest an antibody-drug conjugate (ADC) targeting CXCR4 and LCK could help treat autoimmune

Read the full 195 word article

How to gain access

Continue reading with a
two-week free trial.